Core Viewpoint - Pulsar Helium Inc. has conditionally closed a placing of 9,191,175 common shares at a price of £0.80 per share, raising total gross proceeds of approximately £7.35 million (around US$10 million / CAD$13.7 million) to advance its helium projects [1][2]. Group 1: Financial Details - The placing was priced at £0.80 per share, resulting in gross proceeds of £7,352,940 [1]. - The net proceeds will be utilized for the Topaz helium project in Minnesota, the Falcon project in Michigan, and for general working capital [2]. - An advisory fee of £20,000 and a cash fee of £441,176 were paid to OAK Securities in connection with the placing [3]. Group 2: Project Development - The funds from the placing will support extended well testing, reservoir evaluation, and an additional seismic survey at the Topaz Project [2]. - The company plans to consolidate and expand its mineral and leasehold interests, update the independent resource estimate, and complete a pre-feasibility study for integrated helium and CO₂ production [2]. - A portion of the proceeds will also support exploration activities at the Falcon Project [2]. Group 3: Company Overview - Pulsar Helium Inc. is publicly traded on the AIM market of the London Stock Exchange and listed on the TSX Venture Exchange and OTCQB [9]. - The company focuses on helium projects, with its flagship Topaz project in Minnesota and the Falcon project in Michigan, both identified as primary helium occurrences not associated with hydrocarbon production [9].

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. NOT FOR DISTRIBUTION TO UNITED STATES NEW ...

Core Viewpoint - Pond Technologies Holdings Inc. has extended the deadline to enter into a definitive agreement for a reverse takeover transaction with Find Familiar Spirits LLC to May 31, 2026, after initially announcing the signing of a binding letter of intent on October 28, 2026 [1] Group 1 - The Proposed Transaction involves a business combination where Pond will acquire FFS [1] - The extension of the deadline allows more time for the parties to finalize the agreement [1] - If the definitive agreement is not executed by the new deadline, the letter of intent may be terminated [1] Group 2 - Completion of the Proposed Transaction is subject to several conditions, including regulatory approvals and a concurrent financing [2] - There is no assurance that the Proposed Transaction will be completed as proposed or at all [2] Group 3 - Investors are advised that information regarding the Proposed Transaction may not be accurate or complete unless disclosed in the management information circular or filing statement [3] - The TSX Venture Exchange has not approved or disapproved the contents of the news release [3] Group 4 - The news release contains forward-looking information regarding the Proposed Transaction and associated transactions [4] - Statements about the completion and expected terms of the Proposed Transaction involve risks and uncertainties that may lead to different actual results [4]

Core Viewpoint - Avalon GloboCare Corp. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from warrants [1][3]. Group 1: Financial Details - The private placement involved the issuance and sale of 6,372,550 shares of common stock at a purchase price of $0.51 per share, along with Series A-1 and A-2 warrants [1]. - The gross proceeds from the offering were approximately $3.25 million before deducting fees and expenses, with potential additional gross proceeds of approximately $6.5 million if the warrants are fully exercised [3]. - The net proceeds from the offering will be used for debt repayment, working capital, and general corporate purposes [3]. Group 2: Warrants Information - Series A-1 warrants will expire five years from stockholder approval, while Series A-2 warrants will expire eighteen months from stockholder approval [1]. - The warrants have an exercise price of $0.51 per share and will be exercisable upon stockholder approval [1]. Group 3: Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1]. - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is expanding its intellectual property in cellular therapy and generative AI [6]. - Avalon is also marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA, and plans to pursue additional diagnostic applications [6].

BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update. Pipeline Achievements and Upcoming Milestones ATR-12 - Advancing Phase 1b Clinical Trial in Netherton Syndrome ATR-04 – Addressing an Unmet Need for Cancer Patients in a Multi-billion Dollar Market ...

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) today announced that Janus Living, Inc., a pure-play senior housing real estate investment trust ("REIT†), has publicly filed a registration statement on Form S-11 with the Securities and Exchange Commission (the "SEC†) relating to a proposed initial public offering of its shares of Class A-1 common stock. The offering is subject to market conditions, receipt of regulatory approvals, completion of related financings, completion of the SEC' ...

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of Endeavor Group Holdings, Inc. (NYSE: EDR) Class A common stock between January 15, 2025 and March 24, 2025, both dates inclusive (the “Class Period”), of the important March 18, 2026 lead plaintiff deadline. SO WHAT: If you sold Endeavor Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

Core Viewpoint - The company focuses on helping individual investors achieve financial independence through strategic dividend investing, emphasizing a straightforward method that empowers investors to control their financial future [1] Group 1: Investment Strategy - The investment approach is centered around the motto "Buy Low, Sell High, Get Paid to Wait," which has proven effective in generating reliable income even in volatile markets [1] - The company offers three model portfolios tailored for different investing styles: high yield, high growth, and balanced approach, all of which have outperformed the market since inception [1] Group 2: Tools and Resources - Members gain access to a comprehensive suite of tools, including in-depth analysis of 100 hand-picked dividend stocks and weekly buy/watch/sell lists to facilitate informed decision-making [1] - The proprietary DFT Charts are part of the resources provided to members, enhancing their investment insights [1] Group 3: Community and Support - The company fosters a vibrant community of dividend investors, promoting transparency and engagement, where members can learn from each other and share their investment goals [1] - Support is available for both novice and experienced investors, aiming to help them turn retirement dreams into reality [1]

Core Viewpoint - Femasys Inc. has granted stock options to two new non-executive employees as part of their employment inducement strategy, reflecting the company's commitment to expanding its workforce and enhancing its innovative capabilities in the biomedical sector [1][2]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a broad, patent-protected portfolio of therapeutic and diagnostic products [3]. - The company is actively commercializing its lead product innovations in the U.S. and key international markets, with a focus on enhancing fertility treatment options and permanent birth control solutions [3]. Product Innovations - Femasys' fertility portfolio includes: - FemaSeed Intratubal Insemination (ITI), which has demonstrated more than double the pregnancy rates of traditional IUI with a comparable safety profile [3]. - FemSperm, a sperm preparation and analysis product line [3]. - FemVue, a companion diagnostic for fallopian tube assessment [3]. - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4]. - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4]. Stock Options and Employment Strategy - Femasys granted options to purchase 185,000 shares at exercise prices of $0.50 and $0.57, equal to the closing stock price on the employment date [2]. - The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% each year over the next three years, contingent on continued employment [2].

Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Velox Energy Materials Inc. (TSXV: VLX) ("Velox" or the "Company") is pleased to announce that it proposes to complete a non-brokered private placement financing (the "Private Placement") of up to 89,296,272 units of the Company (the "Units") at a price of $0.035 per Unit, for gross proceeds of up to $3,125,369.52.Each Unit will consist of one common share in the capital of the Company (each, a "Common Share") and one common share purchase warrant (a ...